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AdulterantPsychostimulants such as amphetamine and cocaine are illicitly used drugs that act on neurotransmitter
transporters for dopamine, serotonin or norepinephrine. These drugs can by themselves already cause
severe neurotoxicity. However, an additional health threat arises from adulterant substances which are
added to the illicit compound without declaration. One of the most frequently added adulterants in street
drugs sold as cocaine is the anthelmintic drug levamisole. We tested the effects of levamisole on neuro-
transmitter transporters heterologously expressed in HEK293 cells. Levamisole was 100 and 300-fold less
potent than cocaine in blocking norepinephrine and dopamine uptake, and had only very low afﬁnity for
the serotonin transporter. In addition, levamisole did not trigger any appreciable substrate efﬂux. Because
levamisole and cocaine are frequently co-administered, we searched for possible allosteric effects; at
30 lM, a concentration at which levamisole displayed already mild effects on norepinephrine transport
it did not enhance the inhibitory action of cocaine. Levamisole is metabolized to aminorex, a formerly
marketed anorectic drug, which is classiﬁed as an amphetamine-like substance. We examined the
uptake-inhibitory and efﬂux-eliciting properties of aminorex and found it to exert strong effects on all
three neurotransmitter transporters in a manner similar to amphetamine. We therefore conclude that
while the adulterant levamisole itself has only moderate effects on neurotransmitter transporters, its
metabolite aminorex may exert distinct psychostimulant effects by itself. Given that the half-time of lev-
amisole and aminorex exceeds that of cocaine, it may be safe to conclude that after the cocaine effect
‘‘fades out’’ the levamisole/aminorex effect ‘‘kicks in’’.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Monoamine transporters for serotonin (SERT), norepinephrine
(NET) and dopamine (DAT) belong to the family of Na+/Cl-depen-
dent neurotransmitter transporters and remove their substrates to
end synaptic transmission (Kristensen et al., 2011). Apart from this
physiological role, these transporters are the targets of illicit drugs
like cocaine or amphetamines (Rothman and Baumann, 2003).
Amphetamines lead to a reverse action of all of these transportersand to a number of other intracellular effects which actively in-
crease the concentration of neurotransmitters in the synaptic cleft
(Sitte and Freissmuth, 2010). In contrast, cocaine raises the synap-
tic concentration of monoamines by inhibiting the activity of these
transporters. Both classes of compounds are sold on the street mar-
ket for illicit drugs at the risk of the users because both the quality
and identity of the purchased drugs are without any control. This
situation is alleviated by the government-supported Viennese drug
prevention project ‘checkit! Check your drugs’, which offers cost-
free and anonymous analyses of drugs. Thereby drug consumers
gain information about the contents of their drug as well as possi-
ble risks of those compounds. Importantly and often to the great
surprise of the user, the purchased drug does not contain the com-
pound under the name it was sold. Recently, a survey of unknown
street drugs from the ‘checkit!’ project revealed that a combination
of amphetamine and m-chlorophenylpiperazine (mCPP) was sold
under the name of methylene-dioxymethamphetamine (MDMA,
‘ecstasy’; (Rosenauer et al., 2013)). Hence, the combinations of
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drugs are also adulterated with more or less psychoactive active
compounds: amphetamines are often mixed with e.g. caffeine
(Vanattou-Saifoudine et al., 2012) and cocaine has been found to
be mixed with a wide variety of adulterants. One prominent
example of these adulterants is levamisole (Fig.1A) which has
been found in most of the drug samples sold as cocaine in the
past. Levamisole is used by veterinarians as an anthelmintic
drug (Martin et al., 2012); its mode of action is the stimulation of
ionotropic acetylcholine receptors (AChR) resulting in calcium
inﬂux causing paralysis of the worms (Levandoski et al., 2003;
Rayes et al., 2004). Under the trade name Ergamisol, levamisole
was also used to treat worm infections in humans but had to
be withdrawn from the U.S market in 2000 because of its severe
side-effects (Renoux, 1980). Most recently, several drug consumers
suffered from agranulocytosis after repeated intake of cocaine
adulterated (‘‘cut’’) with levamisole (Muirhead and Eide, 2011;
Wolford et al., 2012).
Several plausible explanations exist why levamisole is used as a
cocaine-adulterant: (i) levamisole was reported to improve the
mood of patients and induced insomnia and hyperalertness (Mutch
and Hutson, 1991). (ii) The chemical properties of levamisole are
similar to cocaine; for instance, color and melting point render
both drugs almost indistinguishable without further chemical
analysis (Chang et al., 2010). (iii) The use of levamisole as a drug
in veterinary medicine makes it easily available and keeps the
costs low (Waller, 2006). (iv) Levamisole was found to be rapidly
metabolized in the human body to aminorex and related metabo-
lites (Hess et al., 2013; Reid et al., 1998). Aminorex (Fig.1A) is an
amphetamine-like agent that was detected in racehorses after lev-
amisole administration (Barker, 2009). Moreover, aminorex was
detected in human urine samples in a multitude of cocaine abusers
(Bertol et al., 2011; Karch et al., 2012). Aminorex was marketed as
an appetite suppressant in the mid-1960s mainly in Switzerland,
Austria, and Germany; it was found to cause pronounced vasocon-
striction in the pulmonary vasculature (Byrne-Quinn and Grover,
1972; Stuhlinger et al., 1969; Rothman et al., 1999) and was with-
drawn in 1972 due to several cases of fatal and life-threatening
pulmonary hypertension (Fishman, 1999a).
In the present work, we examined whether levamisole exerts
direct effects on neurotransmitter transporters and compared
these to the action of its metabolite, aminorex.Table 1
Prevalence of substances traced in 104 samples sold as cocaine.
Substance Prevalence (%)
4-Methylethcathinone 1
Amphetamine 1
Benzocaine 2
Benzoylecgonine 51
cis-Cinnamoylcocaine 15
Caffeine 35
Hydroxyzine 1
Cocaine 93
Mephedrone 1
Levamisole 632. Materials and methods
Dulbecco’s modiﬁed Eagle’s medium (DMEM) and trypsin were
purchased from PAA Laboratories GmbH (Pasching, Austria). Fetal
calf serum was purchased from Invitrogen. [3H]5-HT ([3H]5
-hydroxytryptamine; [3H]serotonin; 28.3 lCi/mmol) and [3H]DA
([3H]dihydroxyphenylethylamine, [3H]dopamine; 46 lCi/mmol)
were purchased from PerkinElmer, Boston, MA. [3H]1-Methyl-4-
phenylpyridinium ([3H]MPP+; 85 lCi/mmol) was supplied by
American Radiolabeled Chemicals (St. Louis, MO). Paroxetine was
from Santa Cruz Biotechnology, mazindole, serotonin, levamisole,
cocaine, aminorex, nisoxetine, D-amphetamine, and monensin
were purchased from Sigma–Aldrich Co.3,4-Methylenedioxy-N-methylamphetamine (MDMA) 2
30 ,40-Methylenedioxy-a-pyrrolidinobutyrophenone
(MDPBP)
1
Lidocaine 18
Methylenedioxypyrovalerone (MDV) 2
Paracetamol 7
Phenacetin 43
Procaine 4
Tetracaine 1
trans-Cinnamoylcocaine 13
Unknown substance 142.1. Sample collection and analysis
The samples used in this study were obtained from drug users
participating voluntarily and anonymously in the ‘checkit!’ drug
prevention program. Three to ten milligrams of substance were
scraped into a tapered 2 ml test vial and weighed with an analyti-
cal balance. The substance was dissolved in 1 mL of methanol and
vortex mixed for 1 min. The solution was centrifuged for 3 min at10,000g in an Eppendorf centrifuge. Ten microliters of the superna-
tant were diluted with 0.4 mL of internal standard solution (trazo-
done 50 lg/mL dissolved in 10 mM aqueous ammonium formate
buffer), 2 ll of the solution was analysed with reversed phase HPLC
and LC/mass spectrometry coupling as described in a previous
study (Rosenauer et al. 2013).2.2. Uptake and release assays
The generation of HEK293 cell lines expressing the human iso-
forms of SERT, NET, or DAT (HEK-SERT, HEK-DAT, or HEK-NET,
respectively) was described earlier (Scholze et al., 2002). HEK293
cells stably expressing either neurotransmitter transporter were
seeded onto poly-d-lysine-coated 96-well plates (40,000 cells/
well), 24 h prior to the experiment. For inhibition experiments,
the speciﬁc activity of the tritiated substrate was kept constant:
[3H]DA, 0.1 lM; [3H]MPP+, 0.015 lM; [3H]5-HT, 0.1 lM. Assay
conditions were used as outlined earlier (Sucic et al., 2010). In
brief, the cells were washed twice with Krebs–Ringer–HEPES buf-
fer (KHB; composition: 25 mM HEPESNaOH, pH 7.4, 120 mM NaCl,
5 mM KCl, 1.2 mM CaCl2, and 1.2 mM MgSO4 supplemented with
5 mM D-glucose). Then, the diluted reference and sample com-
pounds were added and incubated for 5 min to allow for equilibra-
tion with the transporters. Subsequently, the tritiated substrates
were added and the reaction was stopped after 1 min (SERT and
DAT) and 3 min (NET), respectively. Cells were lysed with 1% SDS
and the released radioactivity was quantiﬁed by liquid scintillation
counting. All determinations were performed in duplicate or
triplicate.
For release studies, HEK-SERT, HEK-NET, or HEK-DAT cells were
grown overnight on round glass coverslips (5-mm diameter,
40,000 cells per coverslip) placed in a 96-well plate and preloaded
with 0.4 lM [3H]dopamine, 0.1 lM [3H]MPP+, or 0.4 lM [3H]5-HT
for 20 min at 37 C in a ﬁnal volume of 0.1 mL/well. Coverslips
were then transferred to small superfusion chambers (0.2 ml)
and superfused with KHB (25 C, 0.7 ml min1) as described
(Scholze et al., 2002). A washout period of 40 min established a sta-
ble baseline for efﬂux of radioactivity; thereafter, substances were
added and the experiment was started with the collection of frac-
tions (2 min). At the end of the experiment, cells were lysed in 1%
SDS and the released radioactivity was quantiﬁed by liquid scintil-
lation counting.
Fig. 1A. Chemical structures of cocaine, levamisole and aminorex.
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tional rate (i.e., the radioactivity released within one fraction was
expressed as a percentage of the total radioactivity present in the
cells at the beginning of that fraction). Drug-induced release was
calculated by subtracting the estimated basal release from total re-
lease during the ﬁrst 8 min of drug exposure and is expressed as a
percentage of radioactivity in the cell at the beginning of drug
exposure. Data were normalized by using cpm values with no sub-
stance present (only solvent) as 100%. IC50 values were calculated
using non-linear regression ﬁts performed with Prism software
(GraphPad 5.0, San Diego, CA, U.S.A.). Data transformed into Dixon
plots were ﬁtted by linear regression.Fig. 1B. HPLC mass spectrometry. Representative HPLC chromatogram (UV detection tr
Besides cocaine it also contains signiﬁcant amounts of caffeine, levamisole, phenacetin,2.3. Homology modelling and docking
Levamisole has a pKa value of 7. Both the neutral and proton-
ated levamisole structures were built and minimized with QSite
(version 5.8, Schrödinger, LLC) using the B3LYP method applying
the 6-31G⁄ basis set (Murphy et al., 2000). SERT and NET share over
90% sequence similarity with DAT. Homology models of human
SERT and NET were generated with Modeller 9.12 (Sali and Blun-
dell, 1993) using the validated human DAT model in the outward
facing conformation (Stockner et al., 2013) as template. The best
model out of the 250 generated was used for further studies. The
models of SERT, DAT and NET were energy minimized with Molec-
ular Operating Environment (MOE, 2012) applying the CHARMM22
forceﬁeld (Brooks et al., 2009) and using position restrains of
100 kcal/mol on the backbone.
The induced ﬁt docking protocol of the Schrödinger package was
used for ligand docking into the central binding site (Glide version
5.8, Schrödinger, LLC, New York) using standard parameter setting
(Sherman et al., 2005). The neutral and the protonated form of lev-
amisole were docked as fully ﬂexible molecules. The protonatable
nitrogen of levamisole was constrained to interact with the central
aspartate in the binding side, because the positive amine functional
group of the endogenous substrates of SERT, DAT and NET has beenace at 220 nm) of a cocaine sample which was anonymously delivered to ‘checkit’.
and lidocaine.
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amino acid side chains within 6 Å distance to the ligand were opti-
mized in the OPLS-AA 2005 force ﬁeld after docking. Default energy
levels were employed for selection and ﬁltering of the poses.
The pKa value of aminorex is 7.4. Both, neutral and protonated
form of aminorex were docked using the same methods as for
above levamisole.Fig. 2. Uptake inhibition experiments. Uptake inhibitions with levamisole and
cocaine were performed using HEK 293 cells stably expressing human DAT, NET or
SERT. Therefore cells were incubated with tritiated compounds after a prior
incubation for 5 min with test compound. Uptake of substrate (SERT: 5-HT; NET:
MPP+; DAT: dopamine) at increasing levamisole, respectively cocaine concentra-
tions is expressed as percentage of the maximum uptake without any inhibitory
substance. IC50 values for levamisole (SERT: 1512 ± 1.09 lM; NET: 74.53 ± 1.12 lM;
DAT: 209.9 ± 1.31 lM) (SERT: 1.8 ± 1.12 lM; NET: 1.1 ± 1.07 lM; DAT:3. Results and discussion
In 2012, 104 drug samples were obtained from drug users par-
ticipating voluntarily and anonymously in the ‘checkit!’ program
which were originally purchased as ‘‘cocaine’’. We included all
samples in our study and analyzed them by LC–MS. Two samples
contained pure cocaine whereas seven samples were completely
devoid of cocaine. The remaining 95 samples contained cocaine
in varying amounts (Table 1). Importantly, LC–MS revealed a
number of different adulterants that were mixed to cocaine:
Fig. 1B shows a representative chromatogram. Among others we
found paracetamol, benzoylecgonine, levamisole and phenacetin
(Table 1); levamisole was present in almost two thirds of all exam-
ined samples (66 of 104 samples). The ratio between cocaine and
levamisole in these samples was highly variable. While some sam-
ples contained less than 1% levamisole, one sample even displayed
20 times more levamisole than cocaine. The mean amount of lev-
amisole was 59 ± 22% relative to cocaine. This highly variable
amount of the different drugs also emphasize the risk incurred:
people consume the purchased drug until they experience the
desired effect (Cole et al., 2010). Hence, they are likely to also
consume more of the adulterant.0.56 ± 1.12 lM). Data are mean ± SEM of four independent experiments.3.1. Levamisole inhibits NET, DAT and SERT only at high
concentrations
Given the fact that in our survey levamisole was the most
commonly used adulterant of cocaine, we reasoned that it likely
has pharmacological properties that render it especially useful as
adulterant. This conjecture is justiﬁed, because our ﬁndings are
in line with other reports: levamisole has been observed to be
one of the most predominant adulterants over the past two
decades (Buchanan et al., 2010; Chai et al., 2011). Hence, we ﬁrst
explored whether levamisole exerted an action on the three main
neurotransmitter transporters SERT, NET and DAT using HEK293
cells stably expressing the individual human isoforms of these
transporters. Uptake-inhibition experiments were performed with
increasing concentrations of levamisole or cocaine (Fig. 2). Cocaine
blocked the uptake at the expected concentrations (Ravna et al.,
2003): the observed IC50 values were 1.8 ± 1.12 lM (SERT),
1.0 ± 1.07 lM (NET) and 0.56 ± 1.12 lM (DAT). Levamisole also
reduced the uptake of substrate but at much higher concentra-
tions. Measured IC50 values were 1512 ± 1.09 lM (SERT),
74.5 ± 1.12 mM (NET), 209.9 ± 1.31 lM (DAT). Based on the high
IC50 values of levamisole, it is unlikely that the compound exerts
any signiﬁcant inhibitory action on the transporters in vivo, when
administered in therapeutic doses (e.g., as an adjuvant in cancer
chemotherapy). Oral administration of 50 mg levamisole gives rise
to peak plasma concentrations (cmax) of on average 368 lg/L
(equivalent to about 1.5 lM) (Gwilt et al., 2000). There is a large
intraindividual variation in pharmacokinetics (Gwilt et al., 2000)
and some uncertainty about nasal absorption. In addition, levam-
isole is a highly lipophilic substance that readily permeates the
blood–brain barrier (Lin and Tsai, 2006). Therefore levamisole
may possibly reach higher concentrations than cocaine in the brain
and thereby lead to or support a blockage of NET and DAT, when
consumed at excessive levels.At the very least, the proﬁle of levamisole is reminiscent of that
the action of cocaine at the three transporters, with more promi-
nent inhibition of DAT and NET, and somewhat lower afﬁnity for
SERT. Monoamine transporters have at least two binding sites,
i.e., the SI-site, which corresponds to the substrate binding site
proper, and the SII-site, which resides in the outer vestibule (Chen
and Reith, 2004; Kristensen et al., 2011; Sarker et al., 2010).
Accordingly, we explored the possibility that levamisole exerts
an allosteric effect on the action of cocaine. We performed up-
take-inhibition experiments in HEK293 cells expressing all three
transporters and used increasing cocaine concentrations at a ﬁxed
levamisole concentration or vice versa. Representative experiments
are shown in Fig. 3 for NET. The observations are consistent with
binding of levamisole and cocaine to the same binding site. This
can be best appreciated by examining the transformation of the
data into Dixon plots (Segel, 1975). For this analysis the reciprocal
of uptake velocity is plotted as a function of one inhibitor at a ﬁxed
concentration of the second inhibitor. Regardless of whether lev-
amisole was varied at a ﬁxed cocaine concentration (Fig. 3C and
D) or – vice versa – cocaine was varied at a ﬁxed levamisole concen-
tration (Fig. 3A and B), the transformed data points fell onto paral-
lel lines (Fig. 3B and D). This is indicative of mutually exclusive
binding (Segel, 1975); intersecting lines ought to arise, if cocaine
and levamisole can bind simultaneously, i.e., at two different sites.
Identical experiments were performed for SERT and DAT (Supple-
mentary Figs. S3.1 and S3.2) indicating as well mutually exclusive
binding of levamisole and cocaine.
3.2. Is levamisole an inhibitor to NET, DAT and SERT only – or possibly
a releaser?
Drugs that interact with neurotransmitter transporters can be
either classiﬁed as cocaine-like inhibitors, which trap the trans-
porter in the outward facing conformation and thus interrupt the
Fig. 3. Determination of allosteric interaction between levamisole and cocaine by using uptake inhibition experiments. Uptake inhibitions with levamisole and cocaine were
performed by using HEK 293 cells stably expressing human NET. Uptake of substrate MPP+ at increasing cocaine concentrations at ﬁxed levamisole concentrations (A) is
expressed as percentage of the maximum uptake without any inhibitory substance. IC50 values for cocaine were 0.80 ± 1.45 lM in the absence and 0.23 ± 1.47 lM in the
presence of 30 lM levamisole. Data in (A) were transformed into a Dixon-plot (B) by expressing the reciprocal of MPP+ transported (pmol/million cells/min) as a function of
cocaine at ﬁxed concentrations of levamisole. Equally, uptake of MPP+ at increasing levamisole concentrations at ﬁxed cocaine concentrations (C) is expressed as percentage
of the maximum uptake without substance. IC50 values for levamisole was 521 ± 2.30 lM in the absence and 73 ± 1.47 lM in the presence of 1 lM cocaine. Data in (C) were
transformed into a Dixon-plot (D) by expressing the reciprocal of MPP+ transported (pmol/million cells/min) as a function of levamisole at ﬁxed concentrations of cocaine.
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ers. These raise extracellular monoamine concentrations by trig-
gering substrate efﬂux (Sitte and Freissmuth, 2010). Levamisole
is distantly related in structure to amphetamine. It is therefore
conceivable that levamisole has a releasing action. We increased
the sensitivity of our analysis by co-incubation of the cells with
monensin (Baumann et al., 2013; Scholze et al., 2000; Sitte et al.,
2000). Monensin is an ionophore that promotes electroneutral
Na+/H+ exchange and therefore elevates intracellular Na+ in cells
without altering the membrane potential. Since SERT, NET and
DAT couple substrate transport with symport of Na+ and Cl, eleva-
tion of intracellular Na+ accelerates substrate efﬂux (Sitte and
Freissmuth, 2010). Applications of 5–20 lM monensin have been
found to raise intracellular Na+ to 30–50 mM in HEK293 cells (Chen
and Reith, 2004). In the absence of monensin, no efﬂux was ob-
served in SERT (Fig. 4A) or DAT (Fig. 4C) expressing cells at a high
levamisole concentration (100 lM); however, there was a slight in-
crease in [3H]MPP+ in the superfusate collected from HEK293-NET
cells (Fig. 4C). Importantly, the addition of monensin did notincrease transporter-mediated efﬂux any further (Fig. 4). This ar-
gues for levamisole-mediated inhibition of reuptake of continu-
ously released substrate rather than for a true releasing action.
We previously observed similar spurious releasing effects with
the selective serotonin reuptake inhibitor paroxetine on HEK293-
cells expressing SERT (Scholze et al., 2000). To our knowledge,
the experiments show for the ﬁrst time that levamisole directly
inhibits the human NET and to a lesser extent SERT and DAT. This
inhibition is mediated by a low-afﬁnity interaction with the same
site, to which cocaine is bound and thus the SI site.
3.3. The levamisole-metabolite aminorex modulates NET, SERT and
DAT in a different manner
Administration of levamisole to race horses resulted in positive
doping tests, because their urine contained aminorex (Barker,
2009). The metabolism of levamisole to the amphetamine-like
compound aminorex was later conﬁrmed to also occur in dogs
and humans (Bertol et al., 2011; Hess et al., 2013). Hence, for the
Fig. 4. Releasing effect of levamisole. Substrate efﬂux after treatment with levamisole was measured for SERT (A), NET (B) and DAT (C). HEK 293 cells stably expressing
human SERT, NET or DAT were preloaded with 0.4 lM [3H]5-HT, 0.1 lM [3H]MPP+, or 0.4 lM [3H]dopamine for 20 min at 37 C in a ﬁnal volume of 0.1 mL/well, transferred
to small superfusion chambers (0.2 ml) and superfused with KRH buffer (25 C, 0.7 ml min1). After a washout period of 40 min to reach stable baseline for efﬂux, 10 lM
monensin or buffer (control) was added after 4 min followed by 100 lM levamisole (10 min). Collection of fractions was carried out in 2 min interval. At the end of the
experiment, cells were lysed in 1% SDS. In the absence of monensin we could not detect substrate efﬂux for SERT (A) or DAT (C). However, we observed a slight increased
substrate efﬂux for NET (B) in presence of levamisole compared to the control. Also, we could not detect an effect of monensine alone for any of the three transporters. Data
are shown as mean ± SEM of three independent experiments. Two-way ANOVA (Bonferroni post-test) could not detect signiﬁcant differences in substrate efﬂux between
levamisole and control neither in NET (p = 0.945) nor SERT (p = 0.989) nor DAT (p = 0.678). IC50 values have been calculated using GraphPad Prism 5.04 non-linear regression.
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substrate uptake by NET, SERT or DAT (Fig. 5A). Interestingly,
aminorex also preferentially blocked substrate uptake by NET
(IC50: 0.33 ± 1.07 lM) and DAT (IC50: 0.85 ± 1.20 lM), while SERT
was inhibited only at 20-fold higher concentrations (IC50:
18.39 ± 1.12 lM). Accordingly, the pattern of inhibition (NET >
DAT >>> SERT) was reminiscent of the parent compound levam-
isole, but the inhibitory potency of aminorex was comparable to
that of cocaine. To investigate if cocaine has an allosteric modula-
tory effect on aminorex, we performed uptake-inhibition experi-
ments at increasing concentrations of aminorex in presence of
ﬁxed cocaine concentrations (Fig. 6). The resulting Dixon plots
indicated that aminorex and cocaine bound in a mutually exclusive
manner. In other words, there was not any appreciable allosteric
modulatory effect in SERT, NET or DAT.
Aminorex is classiﬁed as an amphetamine-like substance, be-
cause it is chemically related to amphetamine and it suppresses
feeding behavior in a manner similar to amphetamines. However,
the neurochemical changes induced by aminorex differ from those
of other appetite suppressants (Roszkowski and Kelley, 1963;
Zheng et al., 1997). We therefore investigated its effects on
substrate efﬂux by carrying out superfusion experiments in the
presence and absence of monensin (10 lM). Interestingly, amino-
rex induced signiﬁcant substrate release only in HEK293-SERT cells
whereas efﬂux was completely absent in HEK293-DAT cells.
HEK293-NET cells displayed only a slight response (Fig. 5B-D).
Importantly, monensin enhanced efﬂux as predicted for an
amphetamine-like releaser (Scholze et al., 2000). Taken together
our experimental data showed that aminorex modulates the neu-
rotransmitter transporters in different ways. On the one hand as
an uptake inhibitor at NET and DAT with IC50 values of less than
1 lM but only weakly at SERT, on the other hand it elicits efﬂux
in SERT without overtly affecting NET or DAT. The observation that
aminorex causes signiﬁcant substrate efﬂux only in SERT is coher-
ent with the hypothesis that pulmonary hypertension, a major risk
of aminorex consumption, is caused by dysregulation of peripheral
serotonin transporters (Eddahibi and Adnot, 2002; Pollick, 1999)
Hence, it may be assumed that aminorex has the potential to
potentiate and/or prolong the effect of cocaine in its blocking pro-
pensity. Importantly, it may also prolong the cocaine sensations
because it will elicit transporter-mediated substrate efﬂux owing
to its amphetamine-like properties at times when cocaine is not
present in the brain anymore (Jatlow, 1988; Moolchan et al.,2000). The pharmacokinetic parameters of levamisole are consis-
tent with this hypothesis (Gwilt et al., 2000). This hypothesis is
further supported by a recent analysis of human urine after levam-
isole administration, which showed that aminorex could be de-
tected for up to 54 h (Hess et al., 2013).
Taken together, we demonstrate for the ﬁrst time that levam-
isole directly inhibits the human NET. The metabolite aminorex it-
self modulates NET, DAT and SERT and results in a strong inhibition
of NET and DAT substrate uptake and in substrate efﬂux at SERT. In
addition we could not detect an allosteric modulatory effect of co-
caine on aminorex.
3.4. Understanding the levamisole and aminorex–transporter
interaction by a ligand-docking approach
DAT, NET and SERT are very closely related (Beuming et al.,
2006). The Dixon plots summarized in Fig. 3 provided conclusive
evidence that cocaine and levamisole bound to the same site,
namely SI, the substrate binding site proper. It is difﬁcult to recon-
cile the high degree of conversation in the vicinity of the substrate
binding site and the large differences in afﬁnity of levamisole. Re-
cently, we validated a ligand-based docking approach to probe the
binding pocket of substrates in monoamine transporters (Seddik
et al., 2013). Therefore, we used this computational approach to
understand the discrimination by levamisole against SERT. The
substrate binding sites of DAT and NET are almost identical. They
differ only by one residue in helix 3, namely residue F151 in NET
that corresponds to residue Y155 in DAT (Fig. 7A). Hence, we inves-
tigated, if the phenylalanine – tyrosine substitution explained the
threefold difference in uptake inhibition. As levamisole has a pKa
of 7, we docked both the neutral and the protonated form of
levamisole into the central substrate binding site of the neuro-
transmitter transporter. The positively charged amine functional
group of serotonin, dopamine and norepinephrine has been found
to interact with the sodium coordinating aspartate in the binding
site. We made use of this interaction to reduce the search space
for docking poses and imposed an interaction of the protonatable
nitrogen of levamisole with the conserved aspartate residue (D75
in NET, D79 in DAT and D98 in SERT). Similar docking poses were
observed for both protonation states of levamisole in all three
transporters. The docking score showed the same ranking for both
ligand protonation states. The highest afﬁnity was predicted for
NET (charged: 830 kcal/mol; neutral: 820 kcal/mol), followed
Fig. 5. Inhibitory and releasing effect of aminorex. Uptake of substrate (SERT: 5-HT; NET: MPP+; DAT: dopamine) at increasing aminorex concentrations is shown in (A). IC50
values for aminorex (SERT: 18.39 ± 1.12 lM; NET: 0.33 ± 1.07 lM; DAT: 0.855 ± 1.20 lM) are suggesting a comparable inhibitory effect to cocaine for NET and DAT. For SERT
the inhibitory effect was more than 10-fold higher compared to cocaine (all experiments were performed three times). Substrate efﬂux after treatment with aminorex was
measured for SERT (B), NET (C) and DAT (D). In brief, HEK 293 cells stably expressing human SERT, NET or DAT were preloaded with 0,4 lM [3H]5-HT or 0,1 lM [3H]MPP+ for
20 min at 37 C in a ﬁnal volume of 0.1 mL/well, transferred to small superfusion chambers (0.2 ml) and superfused with KRH buffer (25 C, 0.7 ml min1). After a washout
period of 40 min to reach stable baseline for efﬂux, 10 lM monensin or buffer (control) was added after 4 min followed by 3 or 10 lM aminorex (SERT and NET) and 50 lM
aminorex (DAT) respectively for 10 min. In addition we used 3 lM D-amphetamine as an positive control. Collection of fractions was carried out in 2 min interval. At the end
of the experiment, cells were lysed in 1% SDS. While levamisole lead to an efﬂux of substrate via SERT and NET, which was enhanced by addition of monensin, no releasing
effect of aminorex was observed at DAT (p = 0.9981). A slight increase could be observed in NET (p = 0.001) and aminorex could trigger a strong release in SERT (p < 0.0001).
Data are shown as mean ± SEM of three independent experiments. p-values were calculated using a Two-way ANOVA (Bonferroni post-test).
38 T. Hofmaier et al. / Neurochemistry International 73 (2014) 32–41by DAT (charged: 798 kcal/mol neutral: 792 kcal/mol) and SERT
(charged: 697 kcal/mol neutral: 683 kcal/mol); nevertheless,
scores alone have limited predictive power (Warren et al., 2006)
and require conﬁrmation by other means. This limitation, however,
is less relevant in our approach, because the same ligand is docked
into almost identical binding sites. The observed phenylalanine –
tyrosine substitution between NET and DAT is very conservative,
but it introduces a polar hydroxyl function by contrast with the
hydrophobic phenylalanine side-chain. Importantly, the phenyl
ring of levamisole directly contacts residue F151 in NET or residue
Y155 in DAT in our docking poses, which is consistent with the
experimental data. Our inhibition experiments showed that bind-
ing afﬁnities of levamisole for SERT were lower when compared
to that for NET and DAT. The binding site differs by ﬁve residuesbetween DAT and SERT (residues Y95, G100, I172, Y175 and T497
in SERT) and by four residues between NET and SERT (residue
Y95, G100, I172 and T497 in SERT). Levamisole was found to be
in direct contact with four of these residues. We only observed that
residue T497 was not in direct contact with the inhibitor. In line
with our experimental ﬁndings, the difference in afﬁnity between
SERT and NET or DAT was therefore recapitulated by our computa-
tional approach.
The active metabolite of levamisole (aminorex) binds with com-
parable afﬁnity to DAT and NET, while the afﬁnity to SERT is lower
(see Fig. 5). Aminorex is smaller than levamisole. During our dock-
ing studies of aminorex, we applied the same protocol as used for
levamisole and identiﬁed docking poses in the central binding site
S1. Both, neutral and positively charged forms of aminorex have
Fig. 6. Determination of allosteric interaction between aminorex and cocaine by using uptake inhibition experiments. Uptake inhibitions with aminorex and cocaine were
performed by using HEK cells stably expressing human NET. Uptake of substrate 5-HT, MPP+, and dopamine at increasing cocaine concentrations at ﬁxed aminorex
concentrations (A, C, and E) is expressed as percentage of the maximum uptake without substance. IC50 values for aminorex were 26.29 ± 1.03 lM for SERT (A), 1.97 ± 1.20 lM
for NET (C), and 0.71 ± 1.05 lM for DAT (E) in the absence of cocaine. IC50 values in the presence of constant cocaine concentrations were as follows: SERT: 13.22 ± 1.08 lM at
1 lM Cocaine (A); NET: 0.406 ± 1.13 lM at 0.5 lM Cocaine (C); DAT: 0.20 ± 1.19 lM at 0.5 lM Cocaine. Data in (A, C, and E) were transformed into Dixon-plots (B, D, and F).
The linear regression lines did not intersect, indicating no allosteric modulation of cocaine on aminorex binding. IC50 values have been calculated using GraphPad Prism 5.04
non-linear regression.
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Fig. 7. Docking poses of levamisole. Overlay of the docking poses of levamisole in NET (yellow), DAT (pink) and SERT (grey). The co-transported sodium (blue) and chloride
(orange) ions are shown as spheres. Panel A and B show a zoom into the binding site. For clarity, only the docking poses in DAT is shown. The side chains that are within 5 Å
from the ligand are shown as sticks Panel A: docking of levamisole into the substrate binding site (S1). The phenyl ring of levamisole directly contacts residue F151 in NET or
residue Y155 in DAT. Binding of levamisole in SERT is lower compared to DAT and NET and differs by ﬁve residues between DAT and SERT (residues Y95, G100, I172, Y175 and
T497 in SERT) and by four residues between NET and SERT (residue Y95, G100, I172 and T497 in SERT). Panel B shows overlaid docking poses of aminorex in the central
binding site S1 of SERT, NET and DAT. Aminorex interacts with Y151 in NET and F155 in DAT. Docking pose in SERT showed that aromatic ring of aminorex is not orientated
towards Y175, but inserted between I172 and Y95.
40 T. Hofmaier et al. / Neurochemistry International 73 (2014) 32–41been docked, as the pKa of this psychostimulant is 7.4. We ob-
served similar poses for both protonation states and discuss here
the results of the positively charged state, as endogenous sub-
strates are typically transported in their charged form. The posi-
tively charged nitrogen of aminorex interacts in a similar way
with the aspartate (D75 in NET, D79 in DAT, D98 in SERT) as found
for levamisole or nortriptyline in the recently published dDAT
structure (Penmatsa et al., 2013).
The rank order of the binding energies scores (IFD score) com-
pares favorably with the experimentally found afﬁnities: NET
(822 kcal/mol), DAT (789 kcal/mol) and SERT (693 kcal/mol).
Docking poses revealed overlapping geometries for the interaction
of aminorex with NET and DAT (see Fig. 7B). Aminorex is in direct
contact with Y151 in NET or F155 in DAT which could help to ex-
plain the observed differences in afﬁnity. Importantly, the docking
pose in SERT is different. We ﬁnd that the aromatic ring of amino-
rex is not oriented towards the corresponding residue Y175, but in-
serted between I172 and Y95. Both residues differ in NET and DAT.
We ﬁnd in the corresponding positions V148 and F72 in NET and
V152 and F76 in DAT. These docking results are in line with our
experimental observation of the different behavior in the binding
of aminorex to SERT compared to NET and DAT.4. Conclusions
A large part of illicitly sold drugs are marketed in adulterated
form; these commercialized preparations often may contain sev-
eral additional, also pharmacologically active compounds. There
are two obvious explanations why certain substances are used to
adulterate illicit drugs: substances are added because they are
cheap, have similar chemical appearance and taste and therefore
increase the proﬁt. Alternatively, the additives enhance the
psychoactive effects of the drug by exerting a pharmacological
effect per se. Accordingly, they contribute to the drug-speciﬁc
reinforcement, gain more customers and thus increase proﬁts. To
our knowledge this work demonstrated for the ﬁrst time that
levamisole as cocaine adulterant itself directly inhibits the neuro-
transmitter transporters DAT, SERT and NET. Moreover, we found a
cocaine-like effect of the levamisole metabolite aminorex at the
DAT and the NET and an amphetamine-like effect at SERT.Therefore, it can be assumed that levamisole is used to prolong
the effect of cocaine: it is possible that after the cocaine effect
‘‘fades out’’ the aminorex effect ‘‘kicks in’’. However, the physiolog-
ical consequences of combined cocaine-aminorex administration
are still unclear. To our knowledge there are no reports on how
the combination of cocaine and aminorex inﬂuences drug experi-
ence or brain physiology. It can be assumed that massive elevation
of extracellular serotonin levels not only by inhibiting uptake (via
cocaine) but also increasing efﬂux (via aminorex) can be the
consequence.
The ‘checkit!’ program offers a glimpse into the epidemiology of
the problem:
Two-thirds of the cocaine samples that were analyzed within
the past year were contaminated with moderate to exceedingly
high concentrations of levamisole. The latter highlight the risk
inherent in adulteration of street drugs, namely the occurrence of
severe or life-threatening intoxications. Therefore it is important
to mention that consumption of cocaine adulterated with levam-
isole not only provokes severe agranulocytosis (Buchanan and
Lavonas, 2012) but also induces the risk of pulmonary hyperten-
sion due to aminorex (Fishman, 1999b).
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